| SCHEDULE OF DISAGGREGATION OF REVENUE |
The
following is a summary of the disaggregation of revenue for the three and six months ended June 30, 2026 and 2025:
SCHEDULE OF DISAGGREGATION OF REVENUE
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended | | |
Six Months Ended | |
| | |
June 30, | | |
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Product revenue - distribution services | |
$ | 66,765 | | |
$ | 7,548,600 | | |
$ | 292,430 | | |
$ | 18,216,887 | |
| Pharmacy retail sales | |
| 1,590,367 | | |
| 77,756 | | |
| 2,724,783 | | |
| 192,432 | |
| Third party logistics services | |
| 122,728 | | |
| 164,509 | | |
| 322,210 | | |
| 244,989 | |
| Net revenues | |
$ | 1,779,860 | | |
$ | 7,790,865 | | |
$ | 3,339,423 | | |
$ | 18,654,308 | |
|
| SCHEDULE OF POTENTIALLY DILUTIVE ITEMS OUTSTANDING |
The
following potentially dilutive securities were excluded from the computation of diluted net loss per share for the six months ended June
30, 2026 and 2025:
SCHEDULE OF POTENTIALLY DILUTIVE ITEMS OUTSTANDING
| | |
2026 | | |
2025 | |
| | |
June 30, | |
| | |
2026 | | |
2025 | |
| | |
| | |
| |
| Unvested restricted common stock | |
| 10,714 | | |
| 201,401 | |
| Unissued director share awards | |
| 9,200 | | |
| - | |
| Warrants | |
| 9,442,355 | | |
| - | |
| Convertible notes | |
| 20,323,732 | | |
| - | |
| Total potentially dilutive shares | |
| 29,786,001 | | |
| 201,401 | |
|